Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Caimi

Showing results (61-70 of 115) with videos related to

Pageof 12
Sort By:
Journal of Leukemia (Los Angeles, Calif.)|May 19, 2015
Acidosis Sensing Receptor GPR65 Correlates with Anti-Apoptotic Bcl-2 Family Member Expression in CLL Cells: Potential Implications for the CLL MicroenvironmentAshley E Rosko, Karen S McColl, Fei Zhong, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 5, 2015
Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30(+) Lymphoma Patients Who Received Multiple Prior Lines of TreatmentManuel Afable, Paolo F Caimi, Chitra Hosing, et al.
Leukemia & Lymphoma|January 19, 2021
Efficacy and cost-benefit of filgrastim administered after early assessment bone marrow biopsy during induction therapy for acute myeloid leukemiaJiasheng Wang, Marcos de Lima, Brenda W Cooper, et al.
American Journal of Hematology|April 21, 2020
Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma - specific venous thrombosis prediction modelsGouri Dharmavaram, Shufen Cao, Suchitra Sundaram, et al.
Cells|July 29, 2023
Adjunct Therapy with T Regulatory Cells Decreases Inflammation and Preserves the Anti-Tumor Activity of CAR T CellsKe Zeng, Meixian Huang, Mi-Ae Lyu, et al.
Investigational New Drugs|August 23, 2018
A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphomaTycel Phillips, Paul M Barr, Steven I Park, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 19, 2015
Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk PatientsPaolo F Caimi, Basem M William, Carlos H Silva Rondon, et al.
Journal of Geriatric Oncology|October 23, 2021
SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty toolElizabeth A Brem, Hongli Li, Anne W Beaven, et al.
Bone Marrow Transplantation|February 11, 2023
Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucelAgrima Mian, Wei Wei, Betty K Hamilton, et al.
Haematologica|August 30, 2023
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 studyPaolo F Caimi, Weiyun Z Ai, Juan Pablo Alderuccio, et al.
Pageof 12

Showing results (61-70 of 115) with videos related to

Sort By:
Pageof 12
Journal of Leukemia (Los Angeles, Calif.)|May 19, 2015
Acidosis Sensing Receptor GPR65 Correlates with Anti-Apoptotic Bcl-2 Family Member Expression in CLL Cells: Potential Implications for the CLL MicroenvironmentAshley E Rosko, Karen S McColl, Fei Zhong, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 5, 2015
Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30(+) Lymphoma Patients Who Received Multiple Prior Lines of TreatmentManuel Afable, Paolo F Caimi, Chitra Hosing, et al.
Leukemia & Lymphoma|January 19, 2021
Efficacy and cost-benefit of filgrastim administered after early assessment bone marrow biopsy during induction therapy for acute myeloid leukemiaJiasheng Wang, Marcos de Lima, Brenda W Cooper, et al.
American Journal of Hematology|April 21, 2020
Aggressive lymphoma subtype is a risk factor for venous thrombosis. Development of lymphoma - specific venous thrombosis prediction modelsGouri Dharmavaram, Shufen Cao, Suchitra Sundaram, et al.
Cells|July 29, 2023
Adjunct Therapy with T Regulatory Cells Decreases Inflammation and Preserves the Anti-Tumor Activity of CAR T CellsKe Zeng, Meixian Huang, Mi-Ae Lyu, et al.
Investigational New Drugs|August 23, 2018
A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphomaTycel Phillips, Paul M Barr, Steven I Park, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 19, 2015
Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk PatientsPaolo F Caimi, Basem M William, Carlos H Silva Rondon, et al.
Journal of Geriatric Oncology|October 23, 2021
SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty toolElizabeth A Brem, Hongli Li, Anne W Beaven, et al.
Bone Marrow Transplantation|February 11, 2023
Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucelAgrima Mian, Wei Wei, Betty K Hamilton, et al.
Haematologica|August 30, 2023
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 studyPaolo F Caimi, Weiyun Z Ai, Juan Pablo Alderuccio, et al.
Pageof 12